Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Wyeth

Status and phase: Completed; Phase 1

Conditions: Meningitis, Meningococcal

Treatments: Biological: MnB rLP2086

Study type: Interventional

Funder types: Industry

Identifiers

NCT00297687

6108A1-500

Details and patient eligibility

About

To determine the safety & immunogenicity of a potential vaccine against meningococcal B disease

Sex: All

Ages: 18 to 25 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy 18-25 year olds

Exclusion criteria

• Prior history of vaccination with any meningococcal vaccine
• Prior history of any invasive meningococcal disease

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind